 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
4 News |  |
- || GDC-0334 / Roche, ODM-108 / Orion, ISC 17536 / Ichnos Sciences
Review, Journal: Transient receptor potential ankyrin 1 (TRPA1) antagonists: a patent review (2015-2019). (Pubmed Central) - Feb 4, 2021
During this period, three new molecules entered the clinic (ODM-108, HX-100, and GDC-0334) bringing the total number of TRPA1 antagonists to reach clinical trials to five (including two earlier molecules, CB-625 and GRC 17536); however, to our knowledge, development of all five molecules have been discontinued. Further clinical trials of recent TRPA1 antagonists with good pharmacokinetics would be needed to help understand TRPA1 involvement in human diseases and its potential as a therapeutic target.
- ODM-108 / Orion Corp
Enrollment change, Trial termination, Trial primary completion date: FIMTRIP: Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of ODM-108: in Healthy Male Volunteers (clinicaltrials.gov) - Aug 17, 2016
P1, N=85, Terminated, Sponsor: Orion Corporation, Orion Pharma
N=206 --> 85 | Recruiting --> Terminated | Trial primary completion date: Nov 2016 --> Apr 2016; The study was terminated after the second cohort had completed Part II due complex PK results. There were no safety concerns.
- || ODM-108 / Orion Corp
Trial primary completion date: FIMTRIP: Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of ODM-108: in Healthy Male Volunteers (clinicaltrials.gov) - Apr 4, 2016
P1, N=206, Recruiting, Sponsor: Orion Corporation, Orion Pharma
There were no safety concerns. Trial primary completion date: Apr 2016 --> Nov 2016
- ||| ODM-108 / Orion Corp
New P1 trial: FIMTRIP: Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of ODM-108: in Healthy Male Volunteers (clinicaltrials.gov) - May 12, 2015
P1, N=206, Recruiting, Sponsor: Orion Corporation, Orion Pharma